Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 232

1.

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R.

Oncologist. 2016 Aug 10. pii: theoncologist.2016-0186. [Epub ahead of print]

PMID:
27511905
2.

miR-579-3p controls melanoma progression and resistance to target therapy.

Fattore L, Mancini R, Acunzo M, Romano G, Laganà A, Pisanu ME, Malpicci D, Madonna G, Mallardo D, Capone M, Fulciniti F, Mazzucchelli L, Botti G, Croce CM, Ascierto PA, Ciliberto G.

Proc Natl Acad Sci U S A. 2016 Aug 8. pii: 201607753. [Epub ahead of print]

PMID:
27503895
3.

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P.

Ann Oncol. 2016 Aug 8. pii: mdw291. [Epub ahead of print]

PMID:
27502712
4.

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J.

Lancet Oncol. 2016 Jul 29. pii: S1470-2045(16)30122-X. doi: 10.1016/S1470-2045(16)30122-X. [Epub ahead of print]

PMID:
27480103
5.

Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi.

Strizzi L, Margaryan NV, Gerami P, Haghighat Z, Harms PW, Madonna G, Botti G, Ascierto PA, Hendrix MJ.

Oncol Lett. 2016 Aug;12(2):1349-1354. Epub 2016 Jun 21.

6.

Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors.

Campana LG, Testori A, Curatolo P, Quaglino P, Mocellin S, Framarini M, Borgognoni L, Ascierto PA, Mozzillo N, Guida M, Bucher S, Rotunno R, Marenco F, De Salvo GL, De Paoli A, Rossi CR, Bonadies A.

Eur J Surg Oncol. 2016 Jun 29. pii: S0748-7983(16)30606-0. doi: 10.1016/j.ejso.2016.06.399. [Epub ahead of print]

PMID:
27424789
7.

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.

Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA.

Oncotarget. 2016 Jul 13. doi: 10.18632/oncotarget.10589. [Epub ahead of print]

8.

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.

Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Dastani HB, Waxman IM, Abernethy AP.

Ann Oncol. 2016 Jul 12. pii: mdw265. [Epub ahead of print]

PMID:
27405322
9.

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, Schilling B, Schadendorf D, Wolchok JD, Blank CU, Pawelec G, Garbe C, Weide B.

Eur J Cancer. 2016 Sep;64:116-26. doi: 10.1016/j.ejca.2016.06.001. Epub 2016 Jul 9.

PMID:
27400322
10.

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

Hoeller C, Michielin O, Ascierto PA, Szabo Z, Blank CU.

Cancer Immunol Immunother. 2016 Jul 2. [Epub ahead of print] Review.

PMID:
27372293
11.

Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.

Ascierto PA, Long GV.

Lancet Oncol. 2016 Aug;17(8):1037-9. doi: 10.1016/S1470-2045(16)30017-1. Epub 2016 Jun 17. No abstract available.

PMID:
27324281
12.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E.

Lancet Oncol. 2016 Jul;17(7):883-95. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.

PMID:
27269741
13.

Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma.

Casula M, Colombino M, Manca A, Caracò C, Botti G, Ascierto PA, Lissia A, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI).

J Invest Dermatol. 2016 Sep;136(9):1917-20. doi: 10.1016/j.jid.2016.05.103. Epub 2016 Jun 2. No abstract available.

PMID:
27265006
14.

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, Melero I, Ascierto PA.

Drugs. 2016 Jun;76(9):925-45. doi: 10.1007/s40265-016-0588-x. Review.

PMID:
27229745
15.

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?

Ascierto PA, de Mello RA.

Immunotherapy. 2016 Jun;8(6):681-6. doi: 10.2217/imt-2016-5000.

PMID:
27197537
16.

Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab.

Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler KC, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank CU, Schadendorf D, Dummer R, Ascierto PA, Hospers GA, Garbe C, Wolchok JD.

Clin Cancer Res. 2016 May 16. pii: clincanres.0127.2016. [Epub ahead of print]

PMID:
27185375
17.

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.

Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA, Wolchok JD, Pawelec G, Garbe C, Weide B.

Clin Cancer Res. 2016 May 11. [Epub ahead of print]

PMID:
27169993
18.

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.

De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA, Tafuto S; European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy).

J Transl Med. 2016 May 3;14(1):113. doi: 10.1186/s12967-016-0857-1. Review.

19.

Sun exposure and melanoma prognostic factors.

Gandini S, Montella M, Ayala F, Benedetto L, Rossi CR, Vecchiato A, Corradin MT, DE Giorgi V, Queirolo P, Zannetti G, Giudice G, Borroni G, Forcignanò R, Peris K, Tosti G, Testori A, Trevisan G, Spagnolo F, Ascierto PA; CLINICAL NATIONAL MELANOMA REGISTRY GROUP.

Oncol Lett. 2016 Apr;11(4):2706-2714. Epub 2016 Mar 1.

20.

Editorial: Combination Strategies in the Treatment of Melanoma.

Ascierto PA.

Front Oncol. 2016 Mar 22;6:67. doi: 10.3389/fonc.2016.00067. eCollection 2016. No abstract available.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk